ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Aurinia Pharmaceuticals Inc. (AUPH) stock declined over -1.71%, trading at $8.05 on NASDAQ, down from the previous close of $8.19. The stock opened at $7.89, fluctuating between $7.88 and $8.08 in the recent session.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Employees | 130 |
Beta | 1.27 |
Sales or Revenue | $175.51M |
5Y Sales Change% | 223.378% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |